Results 81 to 90 of about 11,732 (171)

Exploratory single‐nucleus multiomics analysis of myeloid cell states associated with neoadjuvant chemotherapy response in pancreatic ductal adenocarcinoma

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
Neoadjuvant‐treated PDAC tumors were stratified into responders and non‐responders based on CAP guidelines snRNA‐seq, snATAC‐seq, and spatial transcriptomics can be used to profile the neoadjuvant‐chemotherapy‐treated PDAC immune landscape. Our exploratory findings nominate candidate myeloid features for validation in larger cohorts and functional ...
Mercy Ojetunde, Li Ma, Hillary G. Goodney, Alyson M. Stevens, Alan Mizener, Emidio E. Pistilli, Sascha Ott, Kawther Abdilleh, Barbara Szomolay, Gangqing Hu, Timothy D. Eubank, Brian A. Boone   +11 more
wiley   +1 more source

Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort [PDF]

Background: FOLFIRINOX (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) can improve the prognosis of advanced pancreatic ductal adenocarcinoma (PDAC).
de Vos-Geelen, J., Pijnappel, E.N., Laarhoven, H.W.M. van, Verheul, H.M.W., Wilmink, J. W., Stommel, M. W.J., Hooft, J.E. van, Hooft, Jeanin E. van, Wilmink, J.W., Geest, L.G.M. van der, Verheul, H. M.W., van der Geest, L. G.M., van Zweeden, A. A., van Laarhoven, H. W.M., van der Vliet, H. J., Wit, G.F. de, Stommel, M.W.J., Pijnappel, E. N., Zweeden, A.A. van, Vos-Geelen, J. de, Vliet, H.J. van der, Dutch Pancreatic Canc Grp, van Hooft, J. E., de Wit, G. F.   +23 more
core   +1 more source

Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer

, 2021
Background/aim: The purpose of this study was to compare efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine-cisplatin as first-line therapy in ...
Kayahan, Neslihan, Karaca, Mustafa, YAPAR, DİLEK, ÖZET, AHMET, SATIŞ, HASAN   +4 more
core   +1 more source

Multi-Institutional experience with FOLFIRINOX in pancreatic adenocarcinoma [PDF]

, 2012
Combination chemotherapy with FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) was shown to be effective in a large phase III trial.
Suresh, Rama, Wang, Jian, Tan, Benjamin R, McWilliams, Robert, Lubner, Sam, Wang-Gillam, Andrea, Peddi, Parvin Fatheddin, Lockhart, A Craig, Picus, Joel, Wang-Gilliam, Andrea, Peddi, Parvin F, Sorscher, Steven M, Gao, Feng, Linehan, David, Menias, Christine   +14 more
core   +1 more source

Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/ NOTCH/ DDR axis in pancreatic ductal adenocarcinoma

Cell Death and Disease
Chemotherapy resistance has been a great challenge in pancreatic ductal adenocarcinoma(PDAC) treatments. Current first-line chemotherapy regimens for PDAC include gemcitabine-based regimens such as AG regimen (albumin paclitaxel and gemcitabine ...
Qinyuan Jia, Yuheng Zhu, Hongfei Yao, Yifan Yin, Zonghao Duan, Jiahao Zheng, Ding Ma, Minwei Yang, Jianyu Yang, Junfeng Zhang, Dejun Liu, Rong Hua, Yanmiao Huo, Xueliang Fu, Yongwei Sun, Wei Liu   +15 more
doaj   +1 more source

Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience

, 2018
Systemic chemotherapy or chemoradiotherapy is the initial primary option for patients with locally advanced pancreatic cancer (LAPC). This study analyzed the effect of FOLFIRINOX and assessed the factors influencing conversion to surgical resectability ...
Lee, Jong-chan, Gromski, Mark A., Hwang, Jin-Hyeok, Kim, Jaihwan, Kim, Jinwon, Lee, Jongchan, Kim, Hyoung Woo   +6 more
core   +1 more source

FOLFIRINOX for advanced pancreatic cancer::The Princess Margaret experience

, 2015
The FOLFIRINOX regimen has been shown to significantly increase both overall (OS) and progression free (PFS) survival in metastatic pancreas cancer (MPC), albeit with an increase in adverse events (AEs).
Wang, Lisa, Giby, Kazim, Dodd, Anna, Cook, Natalie; id_orcid, Dhani, Neesha C., Hedley, David W., Moore, Malcolm J., Chllamma, Muralidharan   +7 more
core   +5 more sources

Outcomes with FOLFIRINOX for locally advanced pancreatic cancer.

, 2013
256 Background: Trials examining the use of FOLFIRINOX in metastatic pancreatic ductal adenocarcinoma demonstrate significantly higher response rates compared to gemcitabine-based regimens.
Jennifer Steve, Brian A. Boone, Amer H. Zureikat, Ronald Stoller, Michael K. Gibson, Nathan Bahary, Alyssa M. Krasinskas, Barry C. Lembersky, Herbert J. Zeh   +8 more
core   +1 more source

Maintenance therapy with FOLFIRI after FOLFIRINOX for advanced pancreatic ductal adenocarcinoma : a retrospective single-center analysis [PDF]

, 2019
Objectives. Patients with pancreatic ductal adenocarcinoma (PDA) receiving FOLFIRINOX often develop oxaliplatin-induced polyneuropathy, which limits the continuation of this therapy. We evaluated the efficacy and safety of FOLFIRI maintenance treatment
Venerito, Marino, Franck, Caspar, Canbay, Ali E., Malfertheiner, Peter   +3 more
core   +1 more source

Efficacy And Tolerability Of Folfirinox Chemothreapy Regimen İn Pancreaticobiliary Cancer

, 2018
Özet: Bu çalışmanın amacı oksaliplatin, irinotekan, florourasil ve lökoverin kombinasyon tedavisinden oluşan FOLFIRINOX tedavisi ile gemsitabin- sisplatin kombinasyon tedavisinin pankreatobiliyer kanserli hastalardaki etkinlik ve güvenliklerini ...
Dr. Neslihan Kayahan Satış
core